A5024955475- Renal cell carcinoma treatment
- Advanced X-ray and CT Imaging
- Venous Thromboembolism Diagnosis and Management
- Cancer Cells and Metastasis
- Vascular Tumors and Angiosarcomas
- Extracellular vesicles in disease
- Drug Transport and Resistance Mechanisms
- Peroxisome Proliferator-Activated Receptors
- Protease and Inhibitor Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Ovarian cancer diagnosis and treatment
- Cell Adhesion Molecules Research
- Cancer, Lipids, and Metabolism
Shandong Maternal and Child Health Hospital
2025
Shandong First Medical University
2025
Guizhou Provincial People's Hospital
2025
Peking University
2022-2024
Peking University Third Hospital
2022-2024
Abstract Background Surgical treatment for renal cell carcinoma (RCC) and inferior vena cava (IVC) tumor thrombus (TT) is difficult, the postoperative complication rate high. This study aimed to explore safety oncologic outcomes of neoadjuvant stereotactic ablative body radiotherapy (SABR) combined with surgical RCC IVC-TT. Methods Patients IVC-TTs were enrolled in this study. All patients received SABR focused on IVC at a dose 30 Gy 5 fractions, followed by 2 ~ 4 weeks rest. Then, radical...
Zinc finger proteins (ZNFs) have been proved to play important roles in driving the progression of breast cancer (BC), one most common cancers among women. This study aimed investigate involvement zinc-finger SWIM domain-containing protein 3 (ZSWIM3) promoting BC cell by regulating lipid metabolism. Differential expression ZSWIM3 was confirmed comparing its normal human mammary epithelial cells and cells. MCF7 cells, a line, were subjected knockdown/overexpression experiments. The contents...
<title>Abstract</title> Background Cadonilimab, recognized as the most rapidly developed Chinese drug in field of cervical cancer, received marketing approval China 2022. We conducted a study to investigate safety and efficacy combined with without chemotherapy or bevacizumab treatment, patients recurrent / metastatic gynecological malignancies. Methods retrospectively enrolled 60 malignant tumors, confirmed by pathology cytology from July 2022 December 2024. All at least two cycles...
The survival of tumor cells in the bloodstream, and vasculature adhesion at metastatic sites are crucial for metastasis. Perivascular invasion aids cell self-renewal, survival, formation metastases by facilitating readily available oxygen, nutrients, endothelial-derived paracrine factors. Renal carcinoma (RCC) is among most prevalent tumors urinary system, venous thrombus (VTT) a characteristic feature RCC. We observed high expression L1CAM VTT with vessel wall invasion. promotes adhesion,...
In many solid tumors, CD44 has been identified as a cancer stem cell marker well an important molecular in progression and metastasis, making it attractive for potential therapeutic applications. However, our knowledge of the biological function mechanism clear renal carcinoma (ccRCC) is limited.In this study, expression, prognostic values functional enrichment analysis ccRCC were analyzed using public databases. Quantitative real-time PCR (qRT-PCR), Western blotting, immunohistochemical...
Introduction Although surgery is currently the first choice for patients with renal cell carcinoma and vena cava tumour thrombus, difficult, many complications, prognosis of not ideal. Renal sensitive to traditional radiotherapy, but development stereotactic ablative body radiotherapy (SABR) technology characteristics high precision, dose conformity has made reexamined. Methods analysis Study design This trial a single-arm cohort study sponsored by Peking University Third Hospital. treatment...
Abstract Background Surgical treatment for renal cell carcinoma (RCC) and inferior vena cava (IVC) tumor thrombus (TT) is difficult has a high postoperative complication rate. This study aims to explore the safety oncologic outcomes of neoadjuvant stereotactic ablative body radiotherapy (SABR) combined with surgical RCC IVC-TT. Methods Patients IVC-TT were enrolled in this study. All them received SABR focused on IVC at dose 30 Gy 5 fractions, followed by 2 ~ 4 weeks rest. Then, radical...